

# Aetna, AMA Lock Horns Over Medicare Payment

BY JANE ANDERSON  
Contributing Writer

Aetna Inc. announced in January that it is working with the American Medical Association and state medical societies to resolve issues involving nonparticipating physicians after the AMA complained that the insurer was paying those physicians just 125% of Medicare rates and then telling patients that they did not need to pay the rest.

In a letter to Aetna, Dr. Michael Maves, who is AMA's chief executive officer and senior vice president, noted that Aetna's policy, which was implemented last June, fails to take into account different practice costs that are reflected by physicians' billed charges.

**Aetna 'is trying to force physicians back into the fold. ... What we're looking at, in my opinion, is restraint of trade. They are trying to ratchet down physicians' fees.'**

"It is simply arbitrary and capricious for Aetna to deem 125% of Medicare to be a fair payment across the board," Dr. Maves wrote in his letter to Dr. Troyen Brennan, who is Aetna's chief medical officer.

Dr. Maves also noted in the letter that physicians nationwide are reporting receiving Aetna explanation of benefits (EOB) forms stating that the patient has no obligation to pay the nonparticipating physician the difference between the physician's charge and the amount Aetna has paid.

This practice, Dr. Maves said, potentially violates the 2003 settlement agreement with Aetna in Multidistrict Litigation 1334, the large class action lawsuit in which physicians sued large managed care companies, including Aetna, over business practices.

However, Dr. Brennan said in an interview that the settlement in that case "clearly differentiates between HMO-based plans and traditional plans."

That settlement requires Aetna to tell members in traditional plans that they can be balance-billed by nonparticipating physicians, but it treats HMO plans differently, he said.

HMO members receive an EOB stating that Aetna does not contract with a nonparticipating provider, and that the provider might not accept Aetna's payment as payment in full for services, Dr. Brennan said.

"In the notice, we inform the member that we 'seek to ensure that they do not pay this provider any amount above any applicable copayment, coinsurance, or deductible at the in-network (referred) benefit level,' and if they receive a bill for the difference, they should send the bill to us," Dr. Brennan said.

Aetna believes it has complied with the 2003 settlement agreement "in all respects," but is in discussions with the AMA and state medical societies about the issues involved, Dr. Brennan said.

However, "no substantive discussions have occurred as of yet with the AMA," said AMA spokesman Robert Mills.

Meanwhile, nonparticipating physicians are being placed in an awkward situation, said Dr. Alan Schorr, a Langhorne, Pa.-based endocrinologist who does not participate with Aetna.

Dr. Schorr said that some of his patients have received the Aetna explanations of benefits. "This puts the patient and physician into adversarial roles," he comment-

ed, adding that, although Aetna might believe that 125% of Medicare represents fair reimbursement, "the patient has to have some sense of responsibility."

But the explanations of benefits from Aetna state that the patient has no responsibility to pay the difference between 125% of Medicare rates and the actual charges, Dr. Schorr commented in an interview, and patients therefore don't want to pay the difference.

"We've had comments made to our of-

fice manager along the lines of 'Just write off the difference—you make enough anyway,' " he said.

Aetna "is trying to force physicians back into the [network] fold," Dr. Schorr said.

He added that he had complained to the AMA and to the Pennsylvania Medical Society about Aetna's practice.

"What we're looking at, in my opinion, is restraint of trade. They are trying to ratchet down physicians' fees," said Dr. Schorr. ■

For acute, painful musculoskeletal conditions...

## Prompt, Effective Relief With Minimal Sedation<sup>1,2</sup>

Prescribe SKELAXIN® TID/QID to help ensure an effective course of therapy

- Fast-acting with rapid improvement in mobility<sup>1</sup>
- Onset of action occurs within 1 hour with peak plasma levels reached in as early as 2 hours<sup>1</sup>
- Minimal sedation with low incidence of side effects and drowsiness<sup>1,2</sup>
- Well-established safety and efficacy profile<sup>1,2</sup>



Give your patients prompt, effective relief with minimal sedation<sup>1,2</sup>

Prescribe

**Skelaxin® 800mg**  
(metaxalone) Tablets

SKELAXIN® (metaxalone) is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Metaxalone does not directly relax tense skeletal muscles in man.

### Important Safety Information

Taking SKELAXIN® with food may enhance general CNS depression. Elderly patients may be especially susceptible to this CNS effect. The most frequent reactions to metaxalone include nausea, vomiting, gastrointestinal upset, drowsiness, dizziness, headache, and nervousness or "irritability."

Please see full Prescribing Information on adjacent page.

References: 1. Gross L. Metaxalone: a review of clinical experience. *J Neurol Orthop Med Surg.* 1998;18(1):76-79. 2. Dent RW Jr, Ervin DK. A study of metaxalone (Skelaxin) vs. placebo in acute musculoskeletal disorders: a cooperative study. *Curr Ther Res Clin Exp.* 1975;18(3):433-440.